Asley A Sanchez

Mr. Asley A Sanchez


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2024 in Microbiology Research
Verified
Journal Article
Open access
PDF file
ASAsley A Sanchez
Asley A Sanchez
FAFNU Alimiran
FNU Alimiran
KGKushal Gandhi
Kushal Gandhi
SDSamuel David
Samuel David
CBChristopher B Babayco
Christopher B Babayco
GVGary Ventolini
Gary Ventolini
Recently, studies suggest that the protective effects of Lactobacillus within the female reproductive tract may be partly due to their ability to form biofilms. This study aims to explore the possibility that Lactobacillus can produce key mediators to further bolster the survival of biofilms in human vaginal microbiomes. Three bacterial species, namely, Lactobacillus gasseri, L. crispatus, and L. jensenii, sourced from human female subjects were used to carry out experiments examining the growth of biofilms using a microfermenter system. The bacteria were used to inoculate a glass rod spatula which was subsequently transferred to the microfermenter system. The resulting biofilm growing on the glass spatula was harvested in media and stored in a −80 °C freezer for gas chromatography–mass spectroscopy analysis. We found that quorum sensing compounds, acyl homoserine lactones (AHLs), were detected in the biofilm of L. crispatus and L. jensenii, but none were detected in L. gasseri. The biofilm produced by L. crispatus and L. jensenii was much higher in quantity than the biofilm produced by L. gasseri. Aside from oligopeptides quorum sensing, lactobacilli were found to also have AHL compounds that may help them produce more biofilms and improve the survival and growth of their bacterial communities in the female genital area.

27 June 2022 in Journal of Case Reports and Images in Obstetrics and Gynecology
Verified
Journal Article
Open access
PDF file
STSerin Thomas
Serin Thomas
CEChristopher Enakpene
Christopher Enakpene
ASAsley A Sanchez
Asley A Sanchez
GVGary Ventolini
Gary Ventolini
Introduction: The incidence of multiple pregnancies has increased tremendously over the last 3–4 decades due to the advent of assisted reproductive technology treatment. Generally, multifetal pregnancy is associated with increase in maternal and perinatal morbidity and mortality, which are directly proportional with increasing numbers of fetuses in higher order multiple pregnancies. Case Report: We present a case of a 26-year-old G1P0104 female with a 3-year history of anovulatory infertility. After the third cycle of ovarian stimulation with clomiphene citrate, she became pregnant with quadruplets. She had no significant past medical or surgical history. The pregnancy was a tetrachorionictetraamniotic quadruplet and it was relatively uncomplicated during the first and second trimesters. However, the patient had prolonged antepartum admission from 25w6d due to symptomatic preterm uterine contractions. At 31w3d, the patient underwent primary cesarean section due to non-reassuring fetal heart tracing and biophysical profile of quadruplet A. Four viable neonates were delivered, three females and one male. All four quadruplets were admitted to the Neonatal Intensive Care Unit (NICU) with varying degrees of neonatal complications due to prematurity, but they were discharged home between 8 and 9 weeks of life. The placental pathology showed Tenney-Parker changes, but it did not adversely affect the outcome of these infants. Conclusion: Higher-order multifetal pregnancies can pose serious management challenges because of increased preterm delivery. Hence, management should be in a tertiary medical center with a multi-disciplinary team that includes an Obstetrician, Perinatologist, and Neonatologist.

19 October 2022 in Journal of Case Reports and Images in Obstetrics and Gynecology
Verified
Journal Article
Open access
PDF file
KGKushal Gandhi
Kushal Gandhi
JGJohn Garza
John Garza
ASAsley A Sanchez
Asley A Sanchez
AGAsher George
Asher George
SRSanjana Rao
Sanjana Rao
GVGary Ventolini
Gary Ventolini
Introduction: Pelvic organ prolapse is a multifactorial gynecological condition, caused by a disruption of muscles of the pelvic organs. Case Report: A 63-year-old female presented with a history of stress urinary incontinence, dyschezia, and sexual dysfunction. A complete clinical and urogynecological evaluation was performed and diagnoses of uterine and vaginal prolapse and urinary incontinence were made. The patient underwent a vaginal hysterectomy with uterosacral ligament suspension and a vaginal wall repair. The patient’s symptoms resolved following pelvic floor physical therapy. Conclusion: The patient benefited from a vaginal hysterectomy with uterosacral ligament suspension and a vaginal wall repair with subsequent pelvic floor physical therapy treatments.

6 March 2022 in Journal of Case Reports and Images in Obstetrics and Gynecology
Verified
Journal Article
Open access
VKVanessa Ku
Vanessa Ku
SMSrikanth Mukkera
Srikanth Mukkera
NMNathan Joshua Manales
Nathan Joshua Manales
ASAsley A Sanchez
Asley A Sanchez
KGKushal Gandhi
Kushal Gandhi
Introduction: Leflunomide is a disease modifying antirheumatic drug (DMARD) that is commonly used for the treatment of rheumatoid arthritis (RA). It is considered as a category X drug because it is contraindicated during pregnancy (studies in pregnant women have demonstrated a risk to the fetus, and/or human or animal studies have shown fetal abnormalities; risks of the drug outweigh the potential benefits). In women attempting to conceive, it is necessary to ensure that leflunomide levels are undetectable in plasma to prevent the risk of fetal malformations. An 11-day treatment of cholestyramine has been shown to lower leflunomide active metabolite levels to near undetectable levels. Case Report: In this case report, we discuss an RA patient taking leflunomide, who had an unintended pregnancy requiring two treatment courses of cholestyramine for complete washout of leflunomide. A C-section was performed at 39 weeks and 3 days due to concerns about the fetus’ health and was complicated by postpartum hemorrhage. The infant received Apgar scores of 9 and 9 at 1 and 5 minutes. The infant was also found with no birth anomalies and was deemed healthy at a check-up of nine months of age. Conclusion: Although a single 11-day treatment is typically sufficient to safely lower the concentration of leflunomide, it is important to remeasure the leflunomide active metabolite levels after the treatment course of cholestyramine to ensure that levels have reached zero. When leflunomide levels remain significantly elevated, a second treatment course of cholestyramine is required, otherwise the fetus could potentially be exposed to its teratogenic properties.

10 June 2026 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
JHJulia N. Hermann
Julia N. Hermann
SKSophia E Kruger
Sophia E Kruger
NWNatalie Wodniak
Natalie Wodniak
JHJammie Holland
Jammie Holland
VJVeronica Janosick
Veronica Janosick
JHJennifer Head
Jennifer Head
As Valley fever (coccidioidomycosis) vaccine candidates progress towards human trials, a challenge to their eventual introduction is understanding vaccine demand and addressing vaccine hesitancy. We assessed intent to accept a Valley fever vaccine for humans and dogs in two populations living in highly endemic regions: employees at Kern Medical (KM) in Bakersfield, California (N = 103) and members of the public in West Texas (N = 230). We compared the weighted proportions of each population willing to vaccinate themselves and their dogs by demographic and coccidioidomycosis risk factors and assessed the importance of vaccine-related factors on vaccine uptake in each population. We found that 42% (95% confidence interval (CI): 34–49%) of West Texas residents and 76% (95% CI: 63–85%) of KM employees were willing to accept a coccidioidal vaccine, while 49% (95% CI: 41–58%) of West Texas residents and 74% (95% CI: 58–86%) of KM employees were willing to vaccinate their dogs. Among West Texas residents, vaccination willingness was significantly higher among those with prior awareness of Valley fever (adjusted odds ratio (aOR): 3.83, 95% CI: 1.73, 8.49). Across both study populations, absence of side effects was the most important condition that would increase vaccination willingness. Our results indicate substantial interest in a Valley fever vaccine while suggesting that increased Valley fever awareness and minimal vaccine side effects may be important for increased uptake.